The AAPS annual meeting presentation discusses advancements in pharmaceutical development, particularly focusing on the optimization of freeze-dried nanosuspension for IV infusion and the application of rotating disk dissolution (RDD) to evaluate and predict oral bioperformance of drug formulations. Key insights include the importance of diffusion layer modulation in enhancing the solubility and bioavailability of carbamazepine, as well as the role of RDD in solid form selection and formulation design. The presentation also emphasizes the collaborative development of new excipients to meet regulatory challenges and improve pharmaceutical formulations.

1. AAPS-2012 Research Presentations
Pharmaceutical Development US
Boehringer-Ingelheim Pharmaceuticals
AAPS Annual Meeting and Exposition
October 14-18, 2012, McCormick Place, Chicago

3. Optimization of Freeze-dried
Nanosuspension and its Application for IV
infusion

4. Imaging of Slow Releasing API-PVP Amorphous
Solid Dispersion Tablets

6. Rotating Disk Dissolution to Understand and Predict
Bioperformance
Michael Hawley, Pharmaceutical Development US
This presentation discusses the use of the rotating disk
dissolution (intrinsic dissolution) technique during CBZ Summary
How Can We Reformulate?
development to understand dissolution mechanisms 14
•One approach - Diffusion layer modulation
Because Form I converts to
and to assist in the prediction of oral bioperformance. the hydrate most rapidly, it is
12
•Only impacts the diffusion layer, not the bulk fluid
Dog AUC (ugh/mL)
actually less bioavailable 10
Rotating disk dissolution is a very simple, fundamental than Form III, which is less
soluble, but does not convert
8
6
B A
Total Concentration of Base
Salt Solubility
measurement method which can be used to to the hydrate
DLpHM
4 DLKspM
C Depressed Salt Solubility
2
Solid form conversion is 0.2 0.4 0.6 0.8 1
characterize API dissolution both qualitatively and important to bioavailability
for carbamazepine solid
RDD Concentration at 60min (mg/mL)
Supersaturation Ratio
Equilibrium Solubility
Other Solubility Free Base Solubility
quantitatively. In its most straightforward application, forms
Diffusion Layer pH
Figure 5: Schematic depiction of how a diffusion layer modulated solid can impact
the rotating disk dissolution rate can be shown to be Carino et al., Relative Bioavailability Estimation of Carbamazepine Crystal Forms using an Artificial Stomach-Duodenum
Model. J Pharm Sci 95:116-125, 2006
relative supersaturation ratios and therefore precipitation rates. Examples of pH
modulation and Ksp modulation in the diffusion layer are described in the text.
Dog Study Results
proportional to bioavailability. Its more powerful use is RDD of DLM solid (API + citric acid) (2:1)
in understanding dissolution mechanisms and •pH 4 dissolution Diffusion layer pH modulation works (~4x enhancement)
PNU-243672A
designing formulations through awareness of what is 20
0.5
DLpHM Solid 0.45
happening in the diffusion layer. Knowledge of the
Plasma Conc (nM/mL)
Concentration (mg/mL)
15 0.4
0.35
pH modified
0.3
impact of solid form transformations and different 10 0.25
0.2
0.15
Salt Suspension
mechanisms for precipitation on the rotating disk
5
0.1
API Only
0.05
0
0
dissolution rate are critical to formulation design. 0 5 10
Time (min)
15 20
-0.05 0 10
Time (hr)
20 30
Using these facts, examples are shown which take
advantage of the properties of individual molecules to RDD Summary
enhance bioperformance of formulations. In summary, RDD is a simple but powerful tool
rotating disk dissolution is a far reaching technique • Useful for solid form selection
• Identify forms that dissolve well
which can be successfully applied to the problem of • Understand the fundamentals behind formulation performance
understanding and predicting bioperformance. Importance of RDD shape
• Phase transformations
 These are identified by non-linear profiles
 Solid form of pellets can be easily identified
Understanding dissolution
• Diffusion layer conditions can be easily modified in RDD
• RDD can be used to develop better solid forms and formulations

11. Unleashing the Potential of New Excipients: A Way Forward
( excerpt from presentation by Dr K. Horspool (Thurs 18th Oct) in the symposium “ New Excipients:
Unmet Needs, Development and Regulatory Challenges”
•Define a forum for collaborative development of new materials – pharma and
excipient developers. High level objectives:
•Work together to influence agencies in accelerated independent approval of excipients
•Support existing materials of interest – share non-propriety information to build data
set (non clinical safety, clinical safety)
•Jointly define “targets of value” to direct future new material design and development
•Create a shared de-risked portfolio of materials or technologies with open access to
partners